期刊
NEURO-ONCOLOGY
卷 25, 期 3, 页码 433-446出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/noac239
关键词
glioblastoma; immunomodulation; radiotherapy
Cancer treatment for Glioblastoma (GBM) is challenging due to limited survival and high relapse rates. This study explores the potential of immunotherapy targeting in GBM treatment by investigating the immunomodulatory effects of radiotherapy (RT) on tumors. The findings suggest that RT can modify the tumor immunogenicity and highlight the therapeutic potential of immunotherapy in fighting GBM.
Cancer treatment protocols depend on tumor type, localization, grade, and patient. Despite aggressive treatments, median survival of patients with Glioblastoma (GBM), the most common primary brain tumor in adults, does not exceed 18 months, and all patients eventually relapse. Thus, novel therapeutic approaches are urgently needed. Radiotherapy (RT) induces a multitude of alterations within the tumor ecosystem, ultimately modifying the degree of tumor immunogenicity at GBM relapse. The present manuscript reviews the diverse effects of RT radiotherapy on tumors, with a special focus on its immunomodulatory impact to finally discuss how RT could be exploited in GBM treatment through immunotherapy targeting. Indeed, while further experimental and clinical studies are definitively required to successfully translate preclinical results in clinical trials, current studies highlight the therapeutic potential of immunotherapy to uncover novel avenues to fight GBM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据